BioSpace News Archive

Allarity Therapeutics, Inc., a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care announced that the Company’s 2023 Annual Meeting of Stockholders, on January 19, 2023, at 1:00 p.m. was adjourned without any business being conducted.

Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today the filing of a provisional patent application covering the use of survivin-engineered dendritic cells and exosomes for stimulation of anti-cancer immunity.

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS) announced today that it has amended certain financial terms of the $20 million convertible note issued by its partner, Cytovia Therapeutics, LLC (“Cytovia”) in payment of the upfront collaboration consideration provided for pursuant to the research collaboration and non-exclusive license agreement between Cellectis and Cytovia.

The Board of Directors of Sensient Technologies Corporation has declared a regular quarterly cash dividend on its common stock of $0.41 per share.